Ciclopirox HIV clinical trials

A new set of researchers are locking on two drugs which can kill HIV on infected host cells by inducing cell death. Both drugs are also approved for human use in Europe and the United States which makes further developments faster and cost-effective.

Antifungal Drug as Anti-HIV?

Researchers at the Rutgers Medical School have proven efficacy of Ciclopirox, an antifungal drug, in inhibiting HIV gene expression. Under lab settings, Ciclopirox blocks certain important functions of HIV-infected cells and then initiates death by reactivating apoptosis. After removal of Ciclopirox on lab cultures, researchers have found that there was no HIV re-occurrence.

In addition to Ciclopirox, they have also found Deferiprone, a drug used to treat beta-thallasaemia major, capable of causing the same effect on HIV-infected cells. Luckily, both drugs are approved for human use in Europe and the United States which means drug development is quicker and cost-effective compared to those drugs that have to undergo clinical trials and animal studies to get similar approval.

How the Mechanism Works?

Both Ciclopirox and Deferiprone can cause apoptosis or programmed cell death or triggered suicide but drug-induced in cellular level. HIV-infected host cells under lab settings exposed to both drugs commit suicide which paralyses virus function and replication. Programmed cell death is disabled once HIV enters the host cell to fuel and replicated itself.

According to the researchers, there are two ways how drugs work against the virus in cellular level. These are as follows:

1. Inhibition of gene expression of HIV which is required for the virus to adapt and replicate and

2. Jamming the mitochondria or power supply inside cells, which interrupts all energy sources HIV needs to multiply and survive.

Under these circumstances, drug-induced apoptosis sever HIV replication, multiplication and survival inside host cells and may even lead to systemic elimination, a cure we may hope for.

BMC Medical Research Methodology at the 35th Annual Conference of the ..  — BMC Pediatrics
The conference will focus on issues such as design and analysis of clinical trials, methods in biostatistics and development of clinical prediction models.

Popular Q&A

Does the European clinical trials directive really improve clinical trial approval time?

To facilitate and improve clinical research within Europe, the European Union (EU) adopted in 2001 the Clinical Trials Directive (EUCTD). The aim of this study was to compare duration between submission of a clinical drug trial application and approval by regulatory authorities in EU countries regulated by EUCTD vs. EU countries regulated by local legislation and, second, to compare the duration of regulatory approval in Europe vs. the USA and Australia.

Related Posts